FIG. 6.

In vivo administration of the ERβ agonist (WAY200070) in db/db mice enhanced first-phase insulin secretion. A: IGTT performed in db/db mice treated with W10 or vehicle (6–7 mice/group) during a 14-day period. B: Insulin levels during an IGTT performed in the same group of animals. Data are provided as the fold increase in plasma insulin (over basal) at 30 min after the glucose bolus injection. C and D: Measurement of β-cell area (area occupied by insulin-positive cells expressed as a percentage of the total area) and islet size. W10-treated db/db mice showed an increase of pancreatic β-cell mass compared with vehicle-treated db/db mice. E: β-Cell replication measured as the percentage of BrdU-positive cells (6–7 mice/group). Data are mean ± SE. *P < 0.05 versus vehicle (Student t test).